This is the authors' abstract. We don't add key points for this paper.
Iles et al. (1) speculated on the value of development of a specific assay to measure human luteinizing hormone β-core fragment (hLHβcf) without cross-reactivity with human chorionic gonadotropin β-core fragment (hCGβcf). We wish to draw readers’ attention to the fact that we developed and reported such a specific assay for hLHβcf in 1995 (2) and reviewed the applications of this assay in 1996 (3). We wrote (3) that the assay “may have useful applications in tumor marker assays, pregnancy tests, and menopause”. The hLHβcf assay (B505-B503) exhibits 1% cross-reactivity with hLH and 0.1% cross-reactivity with hCGβcf. We found that the assay detects the urinary form of hLHβcf in the urine of normally ovulating women (2). We applied this assay to the urine of postmenopausal women and found significant quantities of hLHβcf but not hCGβcf. The mean concentration of hLHβcf for 107 samples from postmenopausal women was 236 pmol/g creatinine (4). We also measured hCGβcf in the same samples and found that its concentration was one-tenth that of hLHβcf. For hCGβcf, we used our laboratory assay B210-B108 (5), which has 2% cross-reactivity with hLHβcf. These data suggest that to use hCGβcf as a cancer marker, an assay of very high specificity for this molecule is required because of possible cross-reaction with hLHβcf.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
O’Connor et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: